DIVI S LABORATORIES LTD vs INDOCO REMEDIES LTD.
A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and INDOCO REMEDIES LTD. (INDOCO) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs INDOCO on 12 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation31
- Profitability40
- Growth10
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
DIVISLAB takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
DIVISLAB takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
DIVISLAB takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
- − ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
- + ["Company's working capital requirements have reduced from 40.8 days to 21.3 days"]
- − ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 8.25% over past five years.", "Company has a low return on equity of -2.45% over last 3 years.", "Earnings include an other income of Rs.98.3 Cr."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.